Last year 3Spine completed 325 surgeries — 151 were done as part of the Motus study and 174 real-world posterior lumbar fusions. The FDA clinical trial spans across 14 states and includes patients from 23 to 79.
Motus is an alternative to spinal fusion. It earned FDA breakthrough device designation in 2020.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
